Freiburg/Breisgau, Germany, July 10, 2023 – Spindiag GmbH, a start-up company in the field of molecular in-vitro diagnostics, has announced the opening of preliminary insolvency proceedings as a result of challenging market conditions caused by the rapid decline of COVID-19 testing. The company remains operational and is actively seeking strategic investors to support its restructuring plan and growth strategy. The preliminary insolvency administrator is Dr. Gesa Pantaleon. Stemberg from the law firm PSW Pantaleon gen. Stemberg & Partner mbB/Freiburg.
Spindiag has established itself as a trusted and forward-thinking start-up company with its Rhonda® brand. Rhonda® is a point-of-care PCR system that provides fast, accurate and convenient results for a variety of infectious diseases. Since its launch in 2020, the company has performed nearly one million tests for COVID-19 and other infectious diseases such as MRSA and Influenza in healthcare facilities and has built a solid customer base with a focus on hospitals in Germany.
Rhonda® is a point-of-care PCR system that has gained popularity due to its excellent sensitivity and ease of use, resulting in minimal training efforts. Uniquely, standard swab samples can be inserted directly into the test cartridge, eliminating the need for pipetting. Results are available in well under one hour, displayed directly on the device and transmitted digitally to the Rhonda app and hospital HIS/LIS IT systems. While a portfolio for respiratory pathogens i.e., Influenza A/B, RSV, SARS-CoV-2 as well as MRSA is already available, the Rhonda system has the potential to detect up to 36 pathogens from a single specimen and has the potential to incorporate alternative Nucleic Acid Amplification (NAAT) and Immunoassay (IA) technologies as it is based on 15 years of cutting-edge research and engineering. The company is in the process of making the Rhonda® platform even faster, in the range of 15 minutes, as well as developing new, highly relevant applications that also leverage our unique strength of high multiplexing capability at an excellent cost structure.
Dr. Daniel Mark, CEO and co-founder of Spindiag, said: “We stay true to our mission by simply providing diagnostic results of high quality and see ourselves as a technology leader in advancing the access to molecular testing results. We are confident that with the right strategic partner, we can overcome the current challenges and continue to deliver value to our customers and society.”
This is an opportunity for strategic investors to join a company that has already proven its value and potential in the marketplace, serving an enthusiastic customer base. Interested parties may contact Spindiag GmbH at:
Phone: +49 761 600 49 600
About Spindiag GmbH
Spindiag GmbH is an in-vitro diagnostics Start-up based in Freiburg/Breisgau, Germany. The company was founded in 2016 by a team of internationally renowned experts in the fields of microfluidics, lab-on-a-chip technology, and life sciences as a spin-off from Hahn-Schickard and the University of Freiburg. Spindiag aims to provide rapid diagnostic results in a simple manner: its PCR-based rapid testing system Rhonda offers healthcare professionals in hospitals and other healthcare facilities a sustainable platform for reliable infection control at the point of care. Spindiag develops and commercializes its testing system based on proprietary microfluidic technology and has already received numerous awards, including from healthcare experts such as B.Braun in the CODE_n competition and Techniker Krankenkasse together with Handelsblatt in the health-i competition.
In 2021, the Rhonda testing system received the internationally renowned Red Dot Design Award for its outstandingly simple and user-friendly design. The company is certified according to EN ISO 13485.
Rhonda is a registered trademark of Spindiag GmbH.